Active, not recruitingPhase 2NCT06169124
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
Studying Malignant non-epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Elizabeth HoppNRG Oncology
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 37 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2024 – 2027
Study locations (30)
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Helen F Graham Cancer Center, Newark, Delaware, United States
- Medical Oncology Hematology Consultants PA, Newark, Delaware, United States
- Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States
- Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States
- Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho, United States
- Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States
- Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, United States
- Northwestern University, Chicago, Illinois, United States
- Carle at The Riverfront, Danville, Illinois, United States
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, United States
- Carle Physician Group-Effingham, Effingham, Illinois, United States
- Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States
- Northwestern Medicine Grayslake Outpatient Center, Grayslake, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06169124 on ClinicalTrials.govOther trials for Malignant non-epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07189871177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsRadiopharm Theranostics, Ltd
- RECRUITINGPHASE1NCT07216105FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsFate Therapeutics
- RECRUITINGPHASE1NCT06238479A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsEli Lilly and Company
- RECRUITINGPHASE2NCT05872204Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian CancerUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT04644289WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCAGO Research GmbH
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04180371Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionBicycleTx Limited
See all trials for Malignant non-epithelial tumor of ovary →